NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner

New agreement is a significant commercial milestone and the Company’s first with its contract research organization partner Agreement expands NetraMark’s portfolio of AI-driven projects in central nervous system (CNS) disorders TORONTO, July 09, 2026 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company developing advanced artificial […]